Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
RESEARCH TOOLSreports
Holding SYRE?
Track your performance easily
SYRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.07 - $47.97
Previous CloseN/A
Volume84.75K
Average Volume (3M)525.80K
Market Cap
$1.21B
Enterprise Value$1.24B
Total Cash (Recent Filing)$63.50M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)2.2
Beta0.60
Next Earnings
Feb 27, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.21
Shares Outstanding58,706,220
10 Day Avg. Volume592,795
30 Day Avg. Volume525,802
Standard Deviation0.42
R-Squared0.13
Alpha-0.00864
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1192.90
Price to Cash Flow (P/CF)-9.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.40K
Enterprise Value/Ebitda-6.09
Forecast
1Y Price Target
$54.33Price Target Upside163.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Spyre Therapeutics News
PremiumCompany Announcements
Spyre Therapeutics Faces Internal Control Challenges
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsSPY002 could emerge as the most potent TL1A mAb to date, likely with the lowest injection burden, potentially improving anti-inflammatory effect with higher potency.
Market PotentialSpyre's decision to pursue rheumatoid arthritis with its TL1A inhibitor could enable it to be first to market in this large indication, which is estimated to have significant sales potential.
Pipeline DevelopmentThe company's 2025 pipeline update confirms that all events are on track, including significant data releases and study initiations.
Bears Say
Clinical TrialsPh1 data on each asset would be needed before combo dosing can begin in Ph2, indicating delays in potential combination therapies.
Market SentimentShort Interest (% Float) is 19.9%, indicating a significant portion of the market is betting against the stock.
ValuationLead opportunities appear priced in at current levels, suggesting limited immediate upside in valuation.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.92% Insiders
16.42% Mutual Funds
0.06% Other Institutional Investors
63.53% Public Companies and Individual Investors
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $20.07 and its highest was $47.97 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $1.21B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 40 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$0.824 by -$0.536.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -1.02.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 58,706,220 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$1.36 in its last earnings report, missing expectations of -$0.824. Following the earnings report the stock price went up 5.015%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
---
Spyre Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.33 (163.48% Upside)
$54.33 (163.48% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 822.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.35%
12-Months-Change
Fundamentals
Return on Equity
180.16%
Trailing 12-Months
Asset Growth
103.16%
Trailing 12-Months
Company Description
Spyre Therapeutics
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
---
SYRE Stock 12 Month Forecast
Average Price Target
$54.33
▲(163.48% Upside)
Technical Analysis
Axsome Therapeutics
―
AnaptysBio
―
Blueprint Medicines
―
BioMarin Pharmaceutical
―
Corcept Therapeutics
―
Fate Therapeutics
―
Best Analysts Covering SYRE
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+45.60%
reiterated a buy rating 6 days ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +45.60% per trade.
---